The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Improved Biomarkers and Clinical Outcome Measures, 2021Isolating Olfactory Biomarkers of Early Parkinson’s Disease
Study Rationale:
Recently, researchers discovered a specific set of molecules in the oily substance produced by the skin of people with Parkinson’s disease (PD). The findings stemmed from work with a... -
Research Grant, 2021Tagging Genes Associated with Parkinson’s Disease Using the Gene-editing CRISPR Tool
Study Rationale:
Parkinson’s disease (PD) is caused, in part, by genetic alterations that produce defective proteins or perturb normal pathways in the brain. To determine how these alterations lead to... -
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Reprogramming the Brain’s Non-neuronal Support Cells to Generate Functional Dopamine-producing Neurons
Study Rationale:
We have recently demonstrated that a method for converting supportive, non-neuronal brain cells into functional dopamine-producing neurons leads to the complete reversal of symptoms... -
Analysis of Patient-Reported Outcomes from Fox Insight, 2021Investigation of Environmental Factors in Idiopathic and LRRK2-related Parkinson’s Disease
Study Rationale:
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by loss of neurons in the substantia nigra, a brain region that controls motion. This loss leads to... -
Target Advancement Program, 2021Targeting the Body’s Circadian Clock to Improve Sleep Quality in Parkinson’s Disease
Study Rationale:
Chronic sleep disruption is among the most frequently reported and disabling pathological features of Parkinson’s disease (PD). This loss of sleep quality is driven by dysregulation... -
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Using Nanobodies and Peptide Mimetics to Stabilize and Activate Mutant GBA
Study Rationale:
Mutations in the gene encoding the enzyme GBA1 are among the most common genetic risk factors for Parkinson’s disease (PD). These mutations compromise the stability and activity...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.